

NAME Shanghai Xie	POSITION TITLE Postdoctoral Fellow
eRA COMMONS USER NAME	

EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Beijing Normal University, Beijing, China	B.s.	1988	Biology
Beijing Normal University, Beijing, China	M.S.	1991	Biology
The University of Texas M.D. Anderson Cancer Center, Houston, Texas	Ph.D.	2002	Biology

Research and/or Professional Experience:

2002- Postdoctoral Fellow, UT Southwestern Medical Center, Dallas. TX

Abstracts and Meetings:

Xie S, Huang S, Luca M, Gutman M, Reich R, Johnson J, and Bar-Eli M. Expression of MCAM/MUC18 by human melanoma cells leadsto increased tumor growth and metastasis. 88th Annual Meeting of American Association for Cancer Research. San Diego, CA April, 1997.

Xie S, Price P, Ronai Z, and Bar-Eli M. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma. 88th Annual Meeting of American Association for Cancer Research. San Diego, CA . April 1997.

Huang S, Gershenwald , Luca M, Gutman M, **Xie S**, and Bar-Eli M. Molecular mechanism of melanoma Metastasis. 4th International conference on melanoma. Sydney, austrilia, June 1997

Wilson-Rawls J, **Xie S**, Liu J, Laneuville P, and Arlinghaus R. P210 Bcr-Abl interacts with IL-3 receptor and constitutively induces tyrosine phosphorylation of Jak2. 3rd International symposium on CML, Nice, France. August,1996.

Xie S, Liu J, Wu Y, and Arlinghaus R. Multiple domains are involved in Bcr and Bcr-Abl interaction. 40th Annual meeting of Amrica Society of Hematology. Miami Beach, FL. December, 1998

Xie S, Wang Y, Wu Y, and Arlinghaus R. Jak2 activation by Bcr-abl is involved in the transformation of K562 leukemia cells. 41st Annual meeting of Amrica Society of Hematology. New Orleans, LA. December, 1999.

Xie S, Liu J, Sun T, and Arlinghaus R. Bcr-Ablactivates Jak2 by direct tyrosine phosphorylation and Jak2 activation is involved in blocking apoptosis. 42nd Annual meeting of Amrica Society of Hematology. San Francisco, CA. December, 2000.

Quackenbush R, Verstovsek S, Lin H, **Xie S**, Garcia-Manero G, Guo J, Talpez M, Kantarjian H, and Arlinghaus R. The low levels of p230 Bcr-Abl expression that are typically seen in patients with neutrophilic-CML do not transform 32D cells. 42nd Annual meeting of Amrica Society of Hematology. San Francisco, CA. December, 2000.

Arlinghaus R, Hawk N, Sun T, **Xie S**, Wang Y, and Liu J. Inhibition of Bcr-Abl oncoprotein by Bcr requires phosposerine 354. 93rd Annual meeting of America Association for Cancer Research. San Francisco, CA. April 2002.

Xie S, Lin H, Sun T, and Arlinghaus R. Jak2 is involved in c-Myc induction by Bcr-Abl. Annual meeting of Experimental Biology. New Orleans, LA. April, 2002.

Selected Publications:

Luca M, **Xie S**, Gutman M, Huang S, and Bar-Eli M. Abnorlities in the CDKN2(P16 INK4/MTS-1)gene in Human melanoma cells: relevance to tumor growth and Metastasis. Oncogene 11:1199-1402, 1995

- Wilson-Rawls J, **Xie S**, Liu J, Laneuville P, and Arlinghaus R. P210 Bcr-Abl interacts with the interleukin 3 receptor beta chain subunit and constitutively induce its tyrosine phosphorylation. *Cancer Research* 56: 3426-3430, 1996
- Xie S**, Huang S, Luca M, Gutman M, Reich R, Johnson J, and Bar-Eli M. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. *Cancer Research* 57: 2295-2303, 1997
- Xie S**, Price J, Ronai Z, and Bar-Eli M. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma. *Oncogene*. 15: 2069-2075, 1997
- Xie S**, Wang Y, Liu J, Sun T, Wilson M, Smithgall T, and Arlinghaus R.. Involvement of Jak2 tyrosine kinase phosphorylation in Bcr-Abl transformation. *Oncogene* 20: 6188- 6195, 2001.
- Hawk N, Sun T, **Xie S**, Wang Y, Liu J, and Arlinghaus R. Inhibition of the Bcr-Abl oncogene by Bcr requires phosphoserine 354. *Cancer Research* 62: 386-390, 2002.
- Xie S**, Lin H, Sun T, Arlinghaus R. Jak2 is involved in c-Myc induction by Bcr-Abl. *Oncogene* 21: 7137-7146, 2002
- Lin H, Monaco G, Sun T, Ling X, Stephens C, **Xie S**, Belmont J, Arlinghaus R. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia. *Oncogene* 24: 3246-3256, 2005